{
    "clinical_study": {
        "@rank": "30084", 
        "arm_group": [
            {
                "arm_group_label": "Yogurt that contains plant stanol esters", 
                "arm_group_type": "Active Comparator", 
                "description": "Dietary Supplement: Yogurt that contains plant stanol esters"
            }, 
            {
                "arm_group_label": "Placebo yogurt", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dietary Supplement:   Placebo yogurt"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the effect of investigational products on serum LDL cholesterol."
        }, 
        "brief_title": "Lipid-lowering Effect of Plant Stanol Yogurt", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypercholesterolemia", 
            "Hyperlipidemias", 
            "Dyslipidemias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Hyperlipidemias", 
                "Dyslipidemias"
            ]
        }, 
        "detailed_description": {
            "textblock": "Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented.\n      LDL-cholesterol lowering efficacy of the ingredient administered in a yogurt is less well\n      known.\n\n      Study was monitored by Foodfiles"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects must voluntarily sign the informed consent\n\n          -  subjects must be male or female aged 20 to 70 years\n\n          -  subjects must have a serum total cholesterol concentration of  5.2  - 7.5 mmol/l (\n             205 - 290  mg/dl) at the screening visit (visit 1, -2 week)\n\n        Exclusion Criteria:\n\n          -  subjects using lipid lowering medication\n\n          -  subjects using ezetimibe\n\n          -  subjects with bile acid sequestrant medication\n\n          -  subjects with statin therapy\n\n          -  subjects using other medication significantly influencing on lipid values\n\n          -  subjects with diagnosis type 1 or type 2 diabetes\n\n          -  severe obesity (BMI>35.0 kg/m2)\n\n          -  serum fasting triglycerides > 4.0 mmol/l\n\n          -  subjects with any hepatic or renal disorder according to medical history\n\n          -  subjects who have history of myocardial infarction or unstable angina pectoris within\n             six months prior to screening\n\n          -  subjects who have history of coronary artery bypass graft or percutaneous\n             transluminal coronary angioplasty within six months prior to screening\n\n          -  subjects who have history of temporal ischemic attack or stroke within six months\n             prior to screening\n\n          -  subjects who have a history of cancer or other malignant disease within the past five\n             years\n\n          -  subjects with abnormal values of health screening variables measured at screening\n             visit: serum gamma-glutamyltransferase> 2 x upper limit, serum alkaline phosphatase>\n             2 x upper limit or other abnormality in laboratory evaluations considered as\n             clinically significant in the opinion of the study physician\n\n          -  subjects who are consuming more than 15 portions of alcohol / week\n\n          -  subjects who are pregnant or  lactating\n\n          -  subjects using Benecol, Becelpro.activ, Danacol or other plant sterol enriched\n             products within 30 days before visit 2\n\n          -  subjects with severe lactose intolerance, milk allergy or any other intolerance to\n             the ingredients of test products\n\n          -  celiac disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882517", 
            "org_study_id": "PCL_2010_024"
        }, 
        "intervention": [
            {
                "arm_group_label": "Yogurt that contains plant stanol esters", 
                "intervention_name": "Yogurt that contains plant stanol esters", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo yogurt", 
                "intervention_name": "Placebo yogurt", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey"
                }, 
                "name": "Hacettepe University"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Cholesterol Lowering Efficacy of Plant Stanol Ester Yoghurt in a Turkish Population", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in serum LDL cholesterol", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882517"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Raisio Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Raisio Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}